Literature DB >> 11765823

Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion.

M L Cannon1, S S Glazier, L A Bauman.   

Abstract

The authors present the hospital course of a 13-year-old girl with a closed head injury who received a prolonged infusion of propofol for sedation and, subsequently, died as a result of severe metabolic acidosis, rhabdomyolysis, and cardiovascular collapse. The patient had been treated for 4 days at a referring hospital for a severe closed head injury sustained in a fall from a bicycle. During treatment for elevations of intracranial pressure, she received a continuous propofol infusion (100 microg/kg/min). The patient began to exhibit severe high anion gap/low lactate metabolic acidosis, and was transferred to the pediatric intensive care unit at the authors' institution. On arrival there, the patient's Glasgow Coma Scale score was 3 and this remained unchanged during her brief stay. The severe metabolic acidosis was unresponsive to maximum therapy. Acute renal failure ensued as a result of rhabdomyolysis, and myocardial dysfunction with bizarre, wide QRS complexes developed without hyperkalemia. The patient died of myocardial collapse with severe metabolic acidosis and multisystem organ failure (involving renal, hepatic, and cardiac systems) approximately 15 hours after admission to the authors' institution. This patient represents another case of severe metabolic acidosis, rhabdomyolysis, and cardiovascular collapse observed after a prolonged propofol infusion in a pediatric patient. The authors suggest selection of other pharmacological agents for long-term sedation in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11765823     DOI: 10.3171/jns.2001.95.6.1053

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

Review 1.  Comparative tolerability of sedative agents in head-injured adults.

Authors:  Susan C Urwin; David K Menon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Physiological and biochemical principles underlying volume-targeted therapy--the "Lund concept".

Authors:  Carl-Henrik Nordström
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  The syndrome of irreversible acidosis after prolonged propofol infusion.

Authors:  Monisha A Kumar; Victor C Urrutia; Carole E Thomas; Karine J Abou-Khaled; Robert J Schwartzman
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Does Myocardial Necrosis Occur in Rhabdomyolysis?

Authors:  Gabriel M Aisenberg; Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2016-06-01

5.  Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome.

Authors:  Kevin Vernooy; Tammo Delhaas; Olaf L Cremer; José M Di Diego; Antonio Oliva; Carl Timmermans; Paul G Volders; Frits W Prinzen; Harry J G M Crijns; Charles Antzelevitch; Cornelis J Kalkman; Luz-Maria Rodriguez; Ramon Brugada
Journal:  Heart Rhythm       Date:  2006-02       Impact factor: 6.343

Review 6.  [Propofol infusion syndrome].

Authors:  J Motsch; J Roggenbach
Journal:  Anaesthesist       Date:  2004-10       Impact factor: 1.041

Review 7.  Propofol infusion syndrome: an overview of a perplexing disease.

Authors:  Vincenzo Fodale; Enza La Monaca
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Status epilepticus: current treatment strategies.

Authors:  Edward M Manno
Journal:  Neurohospitalist       Date:  2011-01

9.  Surveillance of prescription drug-related mortality using death certificate data.

Authors:  Diane K Wysowski
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study.

Authors:  Russel J Roberts; Jeffrey F Barletta; Jeffrey J Fong; Greg Schumaker; Philip J Kuper; Stella Papadopoulos; Dinesh Yogaratnam; Elise Kendall; Renee Xamplas; Anthony T Gerlach; Paul M Szumita; Kevin E Anger; Paul A Arpino; Stacey A Voils; Philip Grgurich; Robin Ruthazer; John W Devlin
Journal:  Crit Care       Date:  2009-10-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.